http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Biogen (BIIB) Says TECFIDERA Data Confirms Efficacy in Newly Diagnosed MS Patients
-
TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness
-
Biogen Joins in Celebration of World Hemophilia Day
-
Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Patients
-
Biogen (BIIB) Announces Receipt of Positive CHMP Opinion for FLIXABI
-
FLIXABI®, an Infliximab Biosimilar Candidate Referencing Remicade®, Receives Positive CHMP Opinion
-
Biogen (BIIB) Names Michel Vounatsos EVP, Chief Commercial Officer
-
Biogen Appoints Michel Vounatsos Executive Vice President, Chief Commercial Officer
-
Biogen to Present at the Goldman Sachs Alzheimer’s Symposium
-
Biogen to Report First Quarter 2016 Financial Results on April 21, 2016
-
Flex Pharma Reports Year End 2015 Financial Results
-
Biogen to Present at the Cowen and Company 36th Annual Health Care Conference
-
Biogen (BIIB) Announces Positive Opinion from CHMP for Alprolix for Treatment of Haemophilia B
-
Sobi and Biogen receive positive opinion from CHMP for Alprolix® (rFIXFc) for the treatment of haemophilia B
-
Sobi and Biogen Receive Positive Opinion from CHMP for Alprolix® (rFIXFc) for the Treatment of Hemophilia B
-
Biogen Joins Pioneering Target Validation Collaboration
-
Biogen to Present at the Leerink Partners 5th Annual Global Healthcare Conference
-
BENEPALI®, the First Etanercept Biosimilar Referencing Enbrel®, Approved in the European Union
-
Biogen (BIIB), Sobi Present Positive Data on ELOCTATE, ALPROLIX in Hemophilia A and B
-
New Data Show ELOCTATE® and ALPROLIX® May Help Control Target Joint Bleeds in People with Hemophilia A and B
-
Sobi and Biogen’s ELOCTA® (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A
-
Biogen Announces Benepali™ (Etanercept) is the First Biosimilar of Enbrel® to Receive a Positive Opinion from CHMP
-
With global outlook weak, many U.S. companies tighten belts
-
Market Wrap: Citron Slams Valeant; Biden Pulls Out of Presidential Race; Twitter Clipps on Downgrade
-
Pre-Open Stock Movers 10/21: (KLAC) (ISRG) (SNDK) Higher; (SNTA) (VMW) (TWTR) Lower (more...)
-
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Advises Shareholders with Losses to Contact the Firm
-
Results from ZINBRYTA™ (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a Published in the New England Journal of Medicine and Presented at ECT
-
Hillary Clinton All Bark, No Bite with Biotech Tweet
-
Biotechs Pressured Following Clinton Tweet (IBB)
-
PureTech Appoints Michael MacLean as Chief Financial Officer
-
Notable Analyst Rating Changes 8/11: (ADBE) (RAX) (VZ) Upgraded; (AMAT) (KMT) (XON) Downgraded
-
Flex Pharma Reports Second Quarter 2015 Financial Results
-
Biogen and SELF Help Women Reimagine Daily Life with Relapsing Multiple Sclerosis (RMS)
-
Alfred Sandrock, Jr., M.D., Ph.D., Chief Medical Officer of Biogen, Joins Flex Pharma’s Scientific Advisory Board
-
Biogen Inc. (Nasdaq: BIIB) to Ring The Nasdaq Stock Market Opening Bell
-
Biogen Inc. (Nasdaq: BIIB) to Ring The Nasdaq Stock Market Opening Bell
-
FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS
-
Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day
-
European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA™ (Daclizumab High-Yield Process) for Treatment of MS
-
Social Media/Biotech Stocks React as Yellen Says Valuations 'Appear Substantially Stretched'
-
Semi-Annual Changes to the NASDAQ OMX CRD Global Sustainability Index
-
Stocks Choppy With Escalation of Ukraine Violence
-
Stocks Sink; Margin Fears Take Center Stage
-
Blood-Bath in Nasdaq Stocks
-
Notable Analyst Rating Changes 01/08: (RAD) (PNRA) (FLIR) Upgraded; (AMBA) (TWTR) (TCS) Downgraded
-
Notable 52-Week Highs and Lows of the Day 11/25: (WMT) (RAD) (CBST) High; (EBAY) (TWTR) Low
-
Wall Street Hubbub 7/26: A Genzyme (GENZ) Deal Coming, Is Biogen Idec (BIIB) Next, New BP CEO, Goldman Sachs the Movie

